NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. The company's mission is to develop combined therapies for complex diseases, targeting multiple mechanisms in a synergistic manner, whilst utilizing regulatory pathways to bring these drugs to market within short timelines.

NeuroSense is currently conducting a phase 2b clinical trial using PrimeC in people with ALS. They also commenced research into other possible indications for the platform technology, including Alzheimer’s and Parkinson’s diseases. Additionally, the R&D team is studying the mechanisms of action and relevant biomarkers for these diseases.